Yongcan Xu

597 citations
15 papers · 439 indexed · h-index 11
Topics
Cancer-related molecular mechanisms research (9 papers)RNA Research and Splicing (7 papers)RNA modifications and cancer (6 papers)
Partner nations
ChinaUnited States

In The Last Decade

Yongcan Xu

15 papers receiving 438 citations

Peers

Yongcan Xu
Comparison fields: 5 of 46
  • Molecular Biology 378
  • Cancer Research 368
  • Pulmonary and Respiratory Medicine 39
  • Oncology 30
  • Epidemiology 21
Replace Arunagiri Kuha Deva Magendhra Rao with:
Arunagiri Kuha Deva Magendhra Rao India
Su‐Ning Huang China
Huiqing Yin China
Qiyao Zhang China
Orit Zion Israel
Shusen Zheng China
Dongping Mo China
Weijian Zhu China
Lichong Yan China
Cassandra C. Garbutt United States
Yongcan Xu relative to Arunagiri Kuha Deva Magendhra Rao India Arunagiri Kuha Deva Magendhra Rao's profile →
Citations per field
00.5×1.5×2.0×
Arunagiri Kuha Deva Magendhra Rao · 1×
Citations per year

Countries citing papers authored by Yongcan Xu

Since Specialization
Citations

This map shows the geographic impact of Yongcan Xu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yongcan Xu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yongcan Xu more than expected).

Fields of papers citing papers by Yongcan Xu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yongcan Xu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yongcan Xu. The network helps show where Yongcan Xu may publish in the future.

Co-authorship network of co-authors of Yongcan Xu

This figure shows the co-authorship network connecting the top 25 collaborators of Yongcan Xu. A scholar is included among the top collaborators of Yongcan Xu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yongcan Xu. Yongcan Xu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
#WorkIndexed citations
1 4
2 9
3 5
4 12
5 21
6 44
7 35
8 109
9 33
10 16
11 45
12 57
13 20
14 24
15
TMED6-COG8 is a novel molecular marker of TFE3 translocation renal cell carcinoma.
5

About Yongcan Xu

Yongcan Xu is a scholar working on Cancer Research, Molecular Biology and Endocrinology, Diabetes and Metabolism, having authored 15 papers that have together received 439 indexed citations. Recurring topics across this work include Cancer-related molecular mechanisms research (9 papers), RNA Research and Splicing (7 papers) and RNA modifications and cancer (6 papers). The work is most often cited by research in Cancer Research (368 citations), Molecular Biology (378 citations) and Pulmonary and Respiratory Medicine (39 citations). Yongcan Xu has collaborated with scholars based in China and United States. Frequent co-authors include Ming Sun, Xuefei Shi, Xiang Yu, Jiewei Xu, Kaihua Lu, Bin Wang, Xueren Feng, Yan Chen, Zhong Wang and Hao Jiang. Their work appears in journals such as Molecular Therapy, Oncotarget and BMC Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026